Cantor Fitzgerald’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Cantor Fitzgerald’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-74,000	Closed	-$741K	–	817
2022 Q3	$741K	Hold	74,000	–	–	0.02%	460
2022 Q2	$733K	Buy	+74,000	New	+$731K	0.01%	510

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cantor Fitzgerald's EUCR Position: Q4 2022 in Review

Cantor Fitzgerald sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 74,000 shares — an estimated $741K sold.

Cantor Fitzgerald first reported a position in EUCR in Q2 2022 and held it in 2 quarters. The position peaked at $741K in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Cantor Fitzgerald reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Cantor Fitzgerald sold 74,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $741K.
Cantor Fitzgerald first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2022 and held it in 2 quarters.
Cantor Fitzgerald's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $741K in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Cantor Fitzgerald's 13F filing for Q4 2022, filed 14 Feb 2023.